Dr. Jhaveri on T-DM1 in the Neoadjuvant Setting

Partner | Cancer Centers | <b>Perlmutter Cancer Center at NYU Langone</b>

Komal L. Jhaveri, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses T-DM1 for neoadjuvant breast cancer treatment.

Komal L. Jhaveri, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses T-DM1 for neoadjuvant breast cancer treatment.

Jhaveri says T-DM1 is already being looked at in the neoadjuvant setting. In one trial, researchers are looking to incorporate T-DM1 into the upfront setting and will evaluate two arms: docetaxel, carboplatin, and trastuzumab (TCH) versus T-DM1 plus pertuzumab. In the KATHERINE trial, patients who did not achieve pathologic complete response will be randomized to T-DM1 or trastuzumab in the adjuvant setting.

T-DM1 is being used in different ways, Jhaveri says, and it’s utility in the neoadjuvant setting remains to be seen.